Cargando…

The Expression of Programmed Death Ligand 1 and Vimentin in Resected Non-Metastatic Non-Small-Cell Lung Cancer: Interplay and Prognostic Effects

Programmed death ligand 1 (PD-L1) is an immune checkpoint with a role in cancer-related immune evasion. It is a target for cancer immunotherapy and its expression is detected for the use of some immune checkpoint inhibitors in advanced non-small cell lung cancer patients (NSCLC). Vimentin is a key c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bravaccini, Sara, Bronte, Giuseppe, Petracci, Elisabetta, Puccetti, Maurizio, D’Arcangelo, Manolo, Ravaioli, Sara, Tumedei, Maria Maddalena, Maltoni, Roberta, Delmonte, Angelo, Cappuzzo, Federico, Crinò, Lucio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Cell and Developmental Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8669606/ https://www.ncbi.nlm.nih.gov/pubmed/34917615 http://dx.doi.org/10.3389/fcell.2021.772216

Ejemplares similares

The Interplay Between Programmed Death Ligand 1 and Vimentin in Advanced Non-Small-Cell Lung Cancer
por: Bronte, Giuseppe, et al.
Publicado: (2021)

Programmed death ligand 1 expression in early stage, resectable non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2019)

Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2013)

K-Ras Mutations in Non-Small-Cell Lung Cancer: Prognostic and Predictive Value
por: D'Arcangelo, Manolo, et al.
Publicado: (2012)

Cell-Free DNA Variant Sequencing Using CTC-Depleted Blood for Comprehensive Liquid Biopsy Testing in Metastatic Breast Cancer
por: Maltoni, Roberta, et al.
Publicado: (2020)

Easily detectable cytomorphological features to evaluate during ROSE for rapid lung cancer diagnosis: from cytology to histology
por: Ravaioli, Sara, et al.
Publicado: (2016)

Spotlight on Ki67 as a prognostic marker in early breast cancer: all that glitters may not be gold
por: Maltoni, Roberta, et al.
Publicado: (2020)

Tumor-Infiltrating Lymphocytes (TILs) and Risk of a Second Breast Event After a Ductal Carcinoma in situ
por: Farolfi, Alberto, et al.
Publicado: (2020)

Androgen Receptor Expression in Breast Cancer: What Differences Between Primary Tumor and Metastases?
por: Bronte, Giuseppe, et al.
Publicado: (2018)

Androgen receptor in advanced breast cancer: is it useful to predict the efficacy of anti-estrogen therapy?
por: Bronte, Giuseppe, et al.
Publicado: (2018)

Are There Differences in Androgen Receptor Expression in Invasive Breast Cancer in African (Tanzanian) Population in Comparison With the Caucasian (Italian) Population?
por: Bravaccini, Sara, et al.
Publicado: (2018)

Evaluation of Androgen Receptor in Relation to Estrogen Receptor (AR/ER) and Progesterone Receptor (AR/PgR): A New Must in Breast Cancer?
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Spotlight on PSMA as a new theranostic biomarker for bladder cancer
por: Tumedei, Maria Maddalena, et al.
Publicado: (2021)

The impact of progesterone receptor expression on prognosis of patients with rapidly proliferating, hormone receptor-positive early breast cancer: a post hoc analysis of the IBIS 3 trial
por: Bravaccini, Sara, et al.
Publicado: (2020)

Androgen receptor in breast cancer: The “5W” questions
por: Ravaioli, Sara, et al.
Publicado: (2022)

Prognosis of ALK-rearranged non-small-cell lung cancer patients carrying TP53 mutations
por: Canale, Matteo, et al.
Publicado: (2022)

Tumor resident microbiota and response to therapies: An insight on tissue bacterial microbiota
por: Pirini, Francesca, et al.
Publicado: (2023)

Liquid Biopsy for EGFR Mutation Analysis in Advanced Non-Small-Cell Lung Cancer Patients: Thoughts Drawn from a Real-Life Experience
por: Ulivi, Paola, et al.
Publicado: (2021)

Clinical and comparative utility of afatinib in non-small cell lung cancer
por: D’Arcangelo, Manolo, et al.
Publicado: (2014)

PSMA expression: a potential ally for the pathologist in prostate cancer diagnosis
por: Bravaccini, Sara, et al.
Publicado: (2018)

Targeting RET-rearranged non-small-cell lung cancer: future prospects
por: Bronte, Giuseppe, et al.
Publicado: (2019)

Cell-free DNA detected by “liquid biopsy” as a potential prognostic biomarker in early breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2017)

Why the complications of COVID-19 patients differ in elderly and young cancer patients
por: Bravaccini, Sara, et al.
Publicado: (2022)

High Levels of Circulating Monocytic Myeloid-Derived Suppressive-Like Cells Are Associated With the Primary Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis
por: Bronte, Giuseppe, et al.
Publicado: (2022)

Wide Next-Generation Sequencing Characterization of Young Adults Non-Small-Cell Lung Cancer Patients
por: Ulivi, Paola, et al.
Publicado: (2022)

Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC)
por: Vecchiarelli, Silvia, et al.
Publicado: (2018)

Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
por: Canale, Matteo, et al.
Publicado: (2020)

Pancreatic Cancer and Cellular Senescence: Tumor Microenvironment under the Spotlight
por: Cortesi, Michela, et al.
Publicado: (2021)

Chronological age or biological age: What drives the choice of adjuvant treatment in elderly breast cancer patients?
por: Maltoni, Roberta, et al.
Publicado: (2021)

Phase II Study of Dehydroepiandrosterone in Androgen Receptor‐Positive Metastatic Breast Cancer
por: Pietri, Elisabetta, et al.
Publicado: (2018)

Prognostic Role of Circulating miRNAs in Early-Stage Non-Small Cell Lung Cancer
por: Ulivi, Paola, et al.
Publicado: (2019)

The Role of TP53 Mutations in EGFR-Mutated Non-Small-Cell Lung Cancer: Clinical Significance and Implications for Therapy
por: Canale, Matteo, et al.
Publicado: (2022)

Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
por: Danesi, Valentina, et al.
Publicado: (2022)

Predictive Role of Telomerase Activity in the Clinical Outcome of Patients with Benign Lesions of the Uterine Cervix or CIN
por: Bravaccini, Sara, et al.
Publicado: (2012)

CD68, CD163, and matrix metalloproteinase 9 (MMP-9) in breast tumor microenvironment to predict breast cancer survival: are they enough?
por: Bravaccini, Sara, et al.
Publicado: (2019)

Trop-2 Therapy in Metastatic Triple-Negative Breast Cancer in Italy: Clinical Opportunity and Regulatory Pitfalls
por: Bravaccini, Sara, et al.
Publicado: (2021)

Sacituzumab govitecan: a new opportunity in the treatment of refractory metastatic triple-negative breast cancer
por: Maltoni, Roberta, et al.
Publicado: (2022)

An In Vitro Analysis on Polyurethane Foam Blocks of the Insertion Torque (IT) Values, Removal Torque Values (RTVs), and Resonance Frequency Analysis (RFA) Values in Tapered and Cylindrical Implants
por: Comuzzi, Luca, et al.
Publicado: (2021)

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
por: Nicolini, Fabio, et al.
Publicado: (2020)

Fully Human Antibodies for Malignant Pleural Mesothelioma Targeting
por: Nicolini, Fabio, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_mcmo3mc5oo5lcnob1mo22rhmu8